Phaseline

Companies › Latigo Biotherapeutics

Latigo Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LTG-001–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06049095LTG-001Phase 1HealthyOtherSep 2026

From the company's SEC filings

Cash of $401m on 2026-09-30; operating cash outflow about $91m a year; runway about 53 months at that burn, to Feb 2031

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.